We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Whole Genome Sequencing Yields Clinical Information

By LabMedica International staff writers
Posted on 18 Jan 2018
Among acutely ill neonatal intensive care unit (NICU) patients, rapid whole genome sequencing (WGS) offers clinically useful information and substantial cost savings in comparison to the current standard of care.

It has been demonstrated that early diagnosis changes acute care management and that rapid WGS improves clinical care. More...
A new study built on prior work by scientists showing that rapid WGS in neonates led to reduced time to diagnosis and better rates of diagnosis than previous practice.

A team of experts at Rady Children’s Institute for Genomic Medicine (San Diego, CA, USA) enrolled 98 NICU patients who were nominated by a treating physician and whose parents gave consent to participate. Enrolled infants had blood samples taken within 48-72 hours of NICU admission, with polymerase chain reaction-free WGS at 40-45X coverage performed on these samples within 3 to 7 days. The investigators translated into human phenotype ontology terms the phenotypic features of each baby and mapped them to potentially causative genetic diseases. They used commercial tools to align DNA sequences and identify variants. Board-certified geneticists curated all variants and clinicians confirmed all significant results.

In one-third of patients (34/98), rapid WGS yielded a genetic diagnosis, which led to changes in medical management in 28 neonates (80%). For example, unnecessary surgery may have been avoided, medications may have been changed to better target underlying diseases, or families may have been counseled about palliative care. Among the first 42 infants, the investigators calculated that rapid WGS led to USD 1.3 million in net cost savings in comparison to standard care the babies otherwise would have received.

Shimul Chowdhury, PhD, FACMG, the clinical laboratory director and first author of the study, said, “Eventually we would like to see rapid WGS as a reimbursable first-tier test for a proportion of infants in the NICU.” The investigators have launched partnerships with children’s hospitals in California and Minnesota to scale-up the rapid WGS process and to determine its clinical utility, cost-effectiveness, and ease of implementation in different institutions. The study was presented at the Annual meeting of the American Society of Human Genetics held October 17, to October 21, 2017, in Orlando, Florida, USA.

Related Links:
Rady Children’s Institute for Genomic Medicine


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.